PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma

QR Code

PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma

Abstract Immunotherapy targeting programmed cell death 1 (PD-1) and PD-ligand 1 (PD-L1) represents promising treatments for human cancers. Our previous studies demonstrated PD-L1 overexpression in some canine cancers, and suggested the therapeutic potential of a canine chimeric anti-PD-L1 monoclonal...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Naoya Maekawa, Satoru Konnai, Maki Nishimura, Yumiko Kagawa, Satoshi Takagi, Kenji Hosoya, Hiroshi Ohta, Sangho Kim, Tomohiro Okagawa, Yusuke Izumi, Tatsuya Deguchi, Yukinari Kato, Satoshi Yamamoto, Keiichi Yamamoto, Mikihiro Toda, Chie Nakajima, Yasuhiko Suzuki, Shiro Murata, Kazuhiko Ohashi
Format:	article
Langue:	EN
Publié:	Nature Portfolio 2021
Sujets:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Accès en ligne:	https://doaj.org/article/33eb1d45a3ba4b309dbca6e1d44f59bf
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Expression of PD-L1 on canine tumor cells and enhancement of IFN-γ production from tumor-infiltrating cells by PD-L1 blockade.
par: Naoya Maekawa, et autres
Publié: (2014)

A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma
par: Naoya Maekawa, et autres
Publié: (2017)

PD-L1 expression as a predictor of postoperative recurrence and the association between the PD-L1 expression and EGFR mutations in NSCLC
par: Kensuke Kojima, et autres
Publié: (2021)

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
par: Hyun Tae Lee, et autres
Publié: (2017)

Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR.
par: Akram Alwithenani, et autres
Publié: (2021)

Tick saliva-induced programmed death-1 and PD-ligand 1 and its related host immunosuppression
par: Yamato Sajiki, et autres
Publié: (2021)

Targeting PD-1/PD-L1 in lung cancer: current perspectives
par: González-Cao M, et autres
Publié: (2015)

Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
par: Grecea M, et autres
Publié: (2021)

Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer
par: Aurelia Noske, et autres
Publié: (2021)

Endocrine Disorders Induced by PD-1/PD-L1 Inhibitor and Related Treatment
par: LAI Yanliang, et autres
Publié: (2021)

Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
par: Zhitao Li, et autres
Publié: (2021)

Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
par: Utpal Kumar, et autres
Publié: (2021)

Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
par: Min Yu, et autres
Publié: (2021)

Correction: Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
Publié: (2021)

The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10–IL-10R Pathways in Acute Myeloid Leukemia
par: Laura Jimbu, et autres
Publié: (2021)

Depletion of PD-1 or PD-L1 did not affect the mortality of mice infected with Mycobacterium avium
par: Masayuki Nakajima, et autres
Publié: (2021)

Programmed death‐ligand 1 expression in swine chronic infections and enhancement of interleukin‐2 production via programmed death‐1/programmed death‐ligand 1 blockade
par: Otgontuya Ganbaatar, et autres
Publié: (2021)

Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in Ovarian Cancer Patients
par: Anna Pawłowska, et autres
Publié: (2021)

Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer
par: Nitin Roper, et autres
Publié: (2021)

Stomach cancer. Clinical significance of the expression of key components of PD-1/PD-L1 immune checkpoint
par: Olga V. Kovaleva, et autres
Publié: (2021)

Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors
par: Miao Wang, et autres
Publié: (2021)

PD-L1 expression in angiomatoid fibrous histiocytoma
par: Joshua Byers, et autres
Publié: (2021)

Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors.
par: Keller J Toral, et autres
Publié: (2021)

Egr2-independent, Klf1-mediated induction of PD-L1 in CD4+ T cells
par: Shuzo Teruya, et autres
Publié: (2018)

EGCG Inhibits Tumor Growth in Melanoma by Targeting JAK-STAT Signaling and Its Downstream PD-L1/PD-L2-PD1 Axis in Tumors and Enhancing Cytotoxic T-Cell Responses
par: Dinoop Ravindran Menon, et autres
Publié: (2021)

Inhibition of PI3Kδ Differentially Regulates Poly I:C– and Human Metapneumovirus–Induced PD–L1 and PD–L2 Expression in Human Bronchial Epithelial Cells
par: Tomohiro Ogawa, et autres
Publié: (2021)

Correlation Between Peripheral Blood Biomarkers and Efficacy of PD-1/PD-L1 Inhibitors Treatment on Lung Cancer
par: KE Ping, et autres
Publié: (2021)

Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors
par: Sarah J. Dart, et autres
Publié: (2021)

Treatment-Related Adverse Events with PD-1 or PD-L1 Inhibitors: A Systematic Review and Meta-Analysis
par: Yixi Zhang, et autres
Publié: (2021)

Sulforaphane enhances the antitumor response of chimeric antigen receptor T cells by regulating PD-1/PD-L1 pathway
par: Chunyi Shen, et autres
Publié: (2021)

Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov
par: Yang Hu, et autres
Publié: (2021)

Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer
par: Clemens Hinterleitner, et autres
Publié: (2021)

The effect of hypoxia on PD-L1 expression in bladder cancer
par: Vicky Smith, et autres
Publié: (2021)

PD-L1 is an activation-independent marker of brown adipocytes
par: Jessica R. Ingram, et autres
Publié: (2017)

Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling
par: Margherita Passariello, et autres
Publié: (2019)

Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer
par: A. N. Niemeijer, et autres
Publié: (2018)

Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival
par: Peiyi Xie, et autres
Publié: (2021)

Detection of PD-L1 Expression in Temozolomide-Resistant Glioblastoma by Using PD-L1 Antibodies Conjugated with Lipid‑Coated Superparamagnetic Iron Oxide
par: Lee GA, et autres
Publié: (2021)

PD-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome
par: Christine Bekos, et autres
Publié: (2021)

Dl-3-N-Butylphthalide Presents Anti-Cancer Activity in Lung Cancer by Targeting PD-1/PD-L1 Signaling
par: Jiang Q, et autres
Publié: (2021)